Immunomic Therapuetics Inc is categorized under Commercial Biotechnical Research in Rockville, MD .
Immunomic Therapuetics Inc was established in 0, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 8121990 by the NAICS.
If you are seeking more information, feel free to contact Teri Heiland at the company’s single location by writing to 15010 Broschart Road, Rockville, Maryland MD 20850 or by phoning (240) 328-6704. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Immunomic Therapuetics Inc |
| Contact Person: | Teri Heiland |
| Address: | 15010 Broschart Road, Rockville, Maryland 20850 |
| Phone Number: | (240) 328-6704 |
| Website Address: | immunomix.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 8121990 |
| Share This Business: |
Immunomic Therapuetics Inc was started in 0 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 8121990. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Teri Heiland for inquiries that concern Immunomic Therapuetics Inc by calling the company number (240) 328-6704, as your correspondence is most welcome. Additionally, the physical location of the single location of Immunomic Therapuetics Inc can be found at the coordinates 39.10286,-77.20015 as well as the street address 15010 Broschart Road in Rockville, Maryland 20850.
For its online presence, you may visit Immunomic Therapuetics Inc’s website at immunomix.com and engage with its social media outlets through on Twitter and on Facebook.